- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Interventions
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 617
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
- Conditions
- Hematologic Malignancy
- Interventions
- Home Transfusion Program Components
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Platelet Transfusion
- Interventions
- Apheresis platelet collection, Refrigerated storage of apheresis platelets in PAS/plasma, Infusion of aliquot of autologous radiolabeled platelets, In vitro tests
- Procedure · Other · Radiation
- Lead sponsor
- Bloodworks
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cardiovascular Disease
- Interventions
- Hemolink (hemoglobin raffimer IV solution)
- Drug
- Lead sponsor
- Hemosol
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
- Drug · Radiation · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Beta-Thalassemia
- Interventions
- ALS20
- Biological
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia
- Interventions
- White Blood Cell Transfusion
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemoglobinuria, Paroxysmal
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Iron Overload
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
- Interventions
- Fludarabine, Fractionated total body irradiation, Busulfan, Cyclophosphamide, Single dose total body irradiation, Melphalan, Granulocyte-colony stimulating factor, Stem cell transplant, Azacitidine
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- ezatiostat hydrochloride (Telintra®)
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 7
- States / cities
- Concord, California • Aurora, Colorado • Springfield, Illinois + 4 more
- Conditions
- Acute Chest Syndrome, Sickle Cell Disease
- Interventions
- Unfractionated heparin
- Drug
- Lead sponsor
- Craig Seaman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Transfusion Dependent Thalassemia
- Interventions
- Mirasol Red Blood Cells (MIR RBCs), Reference Red Blood Cells (REF RBCs)
- Device
- Lead sponsor
- Terumo BCTbio
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Oakland, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Neurodevelopmental Abnormality
- Interventions
- Randomized to Umbilical Cord Milking at birth, Randomized to Delayed Cord Clamping at birth
- Procedure
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 22 Months to 42 Months
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 10 more
- Conditions
- Cancer of the Bone, Limb Salvage
- Interventions
- Tranexamic Acid, 0.9% sodium chloride
- Drug · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia
- Interventions
- Liberal Cell Transfusion, Restricted red cell transfusion
- Procedure
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 48 Hours
- Enrollment
- 1,824 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- COVID-19
- Interventions
- COVID Convalescent Plasma
- Biological
- Lead sponsor
- Gailen D. Marshall Jr., MD PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Intraventricular Hemorrhage
- Interventions
- V-DCC, Delayed cord clamping, Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels
- Procedure
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 23 Weeks to 31 Weeks
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Prostate Cancer
- Interventions
- Ad-REIC/Dkk-3
- Biological
- Lead sponsor
- Momotaro-Gene Inc.
- Industry
- Eligibility
- 20 Years to 75 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anemia
- Interventions
- Mircera, Darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 11
- States / cities
- Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more
- Conditions
- Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
- Interventions
- ADR-529, Topotecan, G-CSF
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Twin Twin Transfusion Syndrome
- Interventions
- Doppler ultrasound of fetal renal artery
- Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Female only
- Enrollment
- 24 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York